tiakis BIOTECH AG news

tiakis Biotech AG (formerly Proteo Biotech AG) has announced that it has renamed the Company from Proteo Biotech AG to tiakis Biotech AG.

In addition, the Company has launched a new website to provide for a more concise point of contact for its business and research partners.

tiakis Biotech AG (formerly Proteo Biotech AG) has announced that the German BMBF has selected the Company to conduct a clinical phase 1b/2 trial to develop its investigational medical product Tiprelestat as a potential therapeutic for COVID-19.

The aim of the clinical trial is to assess Tiprelestat’s efficacy to attenuate severe disease progression of COVID-19. The Company expects the clinical trial to commence in Q4 2022.

tiakis is very proud to support the ongoing eff

tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). 

tiakis’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene Rabinovitch and Dr. Roham Zamanian, were responsible for the conduct of the investigator-init

tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. tiakis research partners and investigators at Stanford University School of Medicine, Dr. Marlene Rabinovitch and D

tiakis BIOTECH AG today announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that tiakis test site is able to conduct the archiving of documents related to in-house development products in compliance with the Principles of GLP. The establishment of a